Lincomycin, capsules 250 mg 20 pcs

Pharmacotherapeutic group
Antibiotic lincosamide

Pharmacokinetics

Absorption – 30-40% (eating slows down the rate and extent of absorption). Time of reaching maximal drug concentration in plasma (TS max) – 2-3 hours. It penetrates well into lung, liver and kidney tissues, through the placental barrier, into breast milk; in high concentrations it is found in bone tissue and joints. Through the blood-brain barrier (BBB) lincomycin penetrates only slightly; in meningitis its permeability increases.

Partially metabolized in the liver. The half-life of the drug (T1/2) is 5 hours. It is excreted unchanged and as metabolites in the bile and kidneys.

Pharmacodynamics

The antibiotic produced by Streptomyces lincolnensis has a bacteriostatic effect. Inhibits protein synthesis of bacteria due to reversible binding to 50S ribosome subunit, disrupts formation of peptide bonds. It is active against Gram-positive cocci (Staphylococcus spp., Streptococcus spp. including Streptococcus pneumoniae); Haemophilus influenzae; Bacillus anthracis, Mycoplasma spp., Bacteroides spp., Corynebacterium diphtheriae, Clostridium perfringens, Clostridium tetani.

Effective against Staphylococcus spp. resistant to penicillin, tetracyclines, chloramphenicol, streptomycin, cephalosporins (30% of erythromycin-resistant Staphylococcus spp. have cross-resistance to lincomycin). It has no effect on Enterococcus spp (including Enterococcus faecalis), Gram-negative microorganisms, fungi, viruses, protozoa; erythromycin has inferior activity against spore-forming anaerobes, Neisseria spp, Corynebacterium spp. Optimum activity is in alkaline environment (pH 8-8.5). Resistance to lincomycin develops slowly. In high doses it has a bactericidal effect.

Indications

Bacterial infections caused by sensitive microorganisms (primarily staphylococci and streptococci, especially microorganisms resistant to penicillins, as well as allergies to penicillins): subacute septic endocarditis, chronic pneumonia, lung abscess, pleural empyema, pleurisy, otitis, osteomyelitis (acute and chronic), purulent arthritis, postoperative purulent complications, wound infection, skin and soft tissue infections (pyoderma, furunculosis, phlegmon, erysipelas).

Pharmacological effect

Pharmacotherapeutic group
Antibiotic-lincosamide

Pharmacokinetics

Absorption – 30–40% (food intake slows down the rate and extent of absorption). The time to reach the maximum concentration of the drug in plasma (TC max) is 2–3 hours. Penetrates well into the tissues of the lungs, liver, kidneys, through the placental barrier, into breast milk; found in high concentrations in bone tissue and joints. Lincomycin penetrates slightly through the blood-brain barrier (BBB), but with meningitis, permeability increases.

Partially metabolized in the liver. The half-life of the drug (T1/2) is 5 hours. It is excreted unchanged and in the form of metabolites with bile and kidneys.

Pharmacodynamics

The antibiotic produced by Streptomyces lincolnensis has a bacteriostatic effect. Suppresses bacterial protein synthesis due to reversible binding to the 50S ribosomal subunit and disrupts the formation of peptide bonds. Active against gram-positive cocci (Staphylococcus spp., Streptococcus spp., including Streptococcus pneumoniae); Haemophilus influenzae; Bacillus anthracis, Mycoplasma spp., Bacteroides spp., Corynebacterium diphtheriae, Clostridium perfringens, Clostridium tetani.

Effective against Staphylococcus spp. resistant to penicillin, tetracyclines, chloramphenicol, streptomycin, cephalosporins (30% of Staphylococcus spp. resistant to erythromycin are cross-resistant to lincomycin). Does not affect Enterococcus spp (including Enterococcus faecalis), gram-negative microorganisms, fungi, viruses, protozoa; inferior in activity to erythromycin against spore-forming anaerobes, Neisseria spp., Corynebacterium spp. The optimum action is in an alkaline environment (pH 8–8.5). Resistance to lincomycin develops slowly. In high doses it has a bactericidal effect.

Special instructions

During long-term treatment, periodic monitoring of the activity of liver transaminases and kidney function is necessary. Prescription to patients with liver failure is permissible only for “vital” indications. If signs of pseudomembranous enterocolitis appear (diarrhea, leukocytosis, fever, abdominal pain, discharge of blood and mucus with feces), in mild cases it is sufficient to discontinue the drug and prescribe ion exchange resins (colestyramine), in severe cases, replacement of the loss of fluid, electrolytes and protein is indicated, vancomycin – orally, in a daily dose of 0.5–2 g (in 3–4 doses) for 10 days or bacitracin.

For long-term or repeated courses, treatment should be carried out under monitoring of liver and kidney function.

Active ingredient

Lincomycin

Composition

Composition per capsule

Active substance

Lincomycin hydrochloride (in terms of lincomycin) – 0.25 g,

Excipients

Potato starch, sucrose.

Hard gelatin capsules – gelatin, titanium dioxide, methylhydroxybenzoate, propylhydroxybenzoate, acetic acid.

Contraindications

Hypersensitivity, pregnancy (except when necessary for life-saving reasons), severe liver and/or kidney failure; lactation period, children under 3 years of age (for capsules).

With caution

Fungal diseases of the skin, oral mucosa, vagina.

Interaction

Pharmaceutically incompatible with kanamycin, ampicillin, barbiturates, theophylline, calcium gluconate, heparin and magnesium sulfate. Antagonism – with erythromycin, synergism – with aminoglycosides. Antidiarrheal drugs reduce the effect. Strengthens the neuromuscular blockade caused by muscle relaxants.

Storage conditions

List B. In a dry place, protected from light, at a temperature not exceeding 20 ° C.

Keep out of the reach of children.

Shelf life

4 years. Do not use after the expiration date stated on the package.

Manufacturer

Ozon, Russia